COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC:

Get the latest research information from NIH: Menu

Deacylated Ghrelin and Beta Cell Function (UAG)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT01531283
Recruitment Status : Unknown
Verified November 2012 by David Dalessio, University of Cincinnati.
Recruitment status was:  Active, not recruiting
First Posted : February 10, 2012
Last Update Posted : November 14, 2012
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Information provided by (Responsible Party):
David Dalessio, University of Cincinnati

Brief Summary:
Use of human unacylated ghrelin (UAG, also called des-octanoyl ghrelin) to study physiology in healthy subjects. The proposed research is an investigator-initiated study funded by the National Institutes of Health designed to examine the effect of physiologic levels of UAG on the regulation of glucose homeostasis as well as beta cell function.

Condition or disease Intervention/treatment Phase
the Diabetic Process Drug: unacylated ghrelin Drug: acyl ghrelin Drug: combined acyl and desacyl ghrelin Drug: saline Not Applicable

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 30 participants
Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: Single (Participant)
Official Title: Impact of Unacylated Ghrelin on Beta-cell Function in Humans
Study Start Date : February 2011
Estimated Primary Completion Date : April 2013

Arm Intervention/treatment
Experimental: decaylated ghrelin
UAG (4.0 µg/kg/hr)
Drug: unacylated ghrelin
IV, UAG (4.0 µg/kg/hr), one time, duration of study visit (approximately 5 hours)

Experimental: acyl ghrelin
AG (1.0 µg/kg/hr)
Drug: acyl ghrelin
IV, AG (1.0 µg/kg/hr), one time, duration of study visit (approximately 5 hours)

Experimental: combined acyl and desacyl ghrelin
the combination of AG (1 µg/kg/hr) and UAG (4 µg/kg/hr)
Drug: combined acyl and desacyl ghrelin
IV, the combination of AG (1 µg/kg/hr) and UAG (4 µg/kg/hr), one time, for the duration of the study visit (approximately 5 hours)

Placebo Comparator: saline
Drug: saline
IV, saline, one time, for the duration of the study visit(approximately 5 hours)

Primary Outcome Measures :
  1. acute insulin release (AIRg) [ Time Frame: one year ]
    The primary outcome measure will be AIRg. This is calculated as the incremental insulin release,following IV glucose administration. (For the first ten minutes of the study visit.)

Secondary Outcome Measures :
  1. Insulin sensitivity [ Time Frame: one year ]
    1. Insulin sensitivity is quantified as the insulin sensitivity index (SI) using Bergman's minimal model of glucose kinetics from the glucose and insulin results obtained from a FSIGT.

  2. Disposition index [ Time Frame: one year ]
    2. The disposition index (DI) is a measure of β-cell function. It accounts for the modulating effect of insulin sensitivity on β-cell responses. It is calculated as the product of the SI and AIRg

  3. glucose tolerance [ Time Frame: one year ]
    3. Glucose tolerance is measured by glucose disappearance constant. This is calculated as the slope of the natural log of glucose during the study visit, during a set time frame.

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years to 50 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes

Inclusion Criteria:

  1. Apparently healthy men and women. Only premenopausal women who are using an adequate method of contraception at Screening and who agree to continue the contraception during the study will be included. Male subjects do not need to use on birth control.
  2. Ages between 18 and 50 years, inclusive.
  3. BMI between 18.5 and 29.9 kg/m2, inclusive

Exclusion Criteria:

  1. History or clinical evidence of impaired fasting glucose or impaired glucose tolerance or diabetes mellitus, myocardial infarction, history or symptoms of congestive heart failure, history of cancer or anorexia nervosa, history or active liver or renal disease (AST or ALT >2x upper limits of normal, calculated glomerular filtration rate [GFR] <60).
  2. A baseline resting systolic blood pressure of less than 100 mm Hg.
  3. History of growth hormone deficiency or excess disorders (acromegaly, pituitary gigantism, panhypopituitarism); history of adrenal insufficiency or Cushing's disease/syndrome; history of neuroendocrine tumors.
  4. Anemia defined as hematocrit <33%.
  5. Use of medications that alter insulin sensitivity: niacin, glucocorticoids, metformin, thiazolidinediones, exenatide, or atypical anti-psychotics.
  6. Pregnancy or lactation.
  7. BMI <18 kg/m2 or BMI >30 kg/m2; fasting plasma glucose >100 mg/dl and/or 2 hr plasma glucose >140 mg/dl on a 75 g oral glucose tolerance test.
  8. Electrocardiogram (ECG) abnormalities: specifically, myocardial ischemia, previous myocardial ischemia, atrial fibrillation, second or third degree heart block and complete right or left bundle branch block.
  9. Females who are on progesterone-only contraception and those who have irregular menses.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT01531283

Layout table for location information
United States, Ohio
Cincinnati Children's Hospital Medical Center
Cincinnati, Ohio, United States, 45229
Sponsors and Collaborators
David Dalessio
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Layout table for additonal information
Responsible Party: David Dalessio, Professor, University of Cincinnati Identifier: NCT01531283    
Other Study ID Numbers: 10-07-19-04
1R03DK089090-01 ( U.S. NIH Grant/Contract )
First Posted: February 10, 2012    Key Record Dates
Last Update Posted: November 14, 2012
Last Verified: November 2012
Keywords provided by David Dalessio, University of Cincinnati:
unacylated ghrelin
beta cell function